Enanta Pharmaceuticals Inc: 5%+ holders

As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Enanta Pharmaceuticals Inc. The largest reported stake is Janus Henderson Group Plc's, at 12.1%. 10 filings are on record since October 9, 2025 (Schedule 13G, November 7, 2025).

Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies ↓

Sell to companies like Enanta Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-10-27 · Holder: BlackRock Portfolio Management LLC · Percent: 5.4% · SCHEDULE 13G
• Filing 2026-08-14 · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 2,418,202 · Sole dispositive: 0 · Shared dispositive: 2,418,202 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-08-14 · Holder: Deep Track Capital, LP · Percent: 4.97% · SCHEDULE 13G/A
• Filed 2026-03-26 · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
• Filed 2026-02-13 · Holder: Deep Track Capital, LP · Percent: 6.78% · SCHEDULE 13G/A

Enanta Pharmaceuticals Inc has 10 Schedule 13D or 13G filings on record since 2025-10-09. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Enanta Pharmaceuticals Inc and the warning signs.

See Enanta Pharmaceuticals Inc's free Snapshot Watch Enanta Pharmaceuticals Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Enanta Pharmaceuticals Inc and the records around it.

Enanta Pharmaceuticals Inc elsewhere on the record

• Leadership changes Oct 2026
• Who owns it

Companies that share a holder

• Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), InflaRx N.V. (Aug 2026), Savara Inc. (Aug 2026)
• Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
• Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)

Want the whole picture on Enanta Pharmaceuticals Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Enanta Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Enanta Pharmaceuticals Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Enanta Pharmaceuticals Inc by CUSIP 29251M106 and gives its principal executive office as 4 KINGSBURY AVENUE, WATERTOWN, MA 02472 (SCHEDULE 13G, 2026-10-27).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Enanta Pharmaceuticals Inc

Who owns Enanta Pharmaceuticals Inc?

On this page, 4 holders' latest ownership filings report 5% or more of Enanta Pharmaceuticals Inc: Janus Henderson Group Plc (12.1%, Schedule 13G, filed 2025-11-07), Dapice Joshua J. (9.8%, Schedule 13G/A, filed 2026-02-05), Farallon Capital Management, L.L.C. (8.3%, Schedule 13G/A, filed 2026-08-14) and BlackRock Portfolio Management LLC (5.4%, Schedule 13G, filed 2026-10-27).

Who are the largest shareholders of Enanta Pharmaceuticals Inc?

By the share each holder's latest filing reports, the largest holders of Enanta Pharmaceuticals Inc on this page are Janus Henderson Group Plc (12.1%), Dapice Joshua J. (9.8%) and Farallon Capital Management, L.L.C. (8.3%).

When did Janus Henderson Group Plc buy into Enanta Pharmaceuticals Inc?

The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2025-11-07, reporting 12.1%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Enanta Pharmaceuticals Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Enanta Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Enanta Pharmaceuticals Inc is mentioned again
• Find former Enanta Pharmaceuticals Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes